VRDN Q3 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+83.5% YoY

Gross Profit

-$3M-207.7% margin

Operating Income

-$6M-361.1% margin

Net Income

-$6M-357.7% margin

EPS (Diluted)

$-4.06

QoQ Revenue Growth

+127.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$679,000

Balance Sheet

Total Assets

$47M

Total Liabilities

$8M

Stockholders' Equity

$39M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$889,000	+83.5%
Gross Profit	-$3M	$290,000	-1267.9%
Operating Income	-$6M	-$2M	-224.3%
Net Income	-$6M	-$2M	-217.2%